uniQure Announces Financial Results For Third Quarter 2016 and Provides Update on Company Progress
22 nov. 2016 07h06 HE
|
uniQure N.V.
~ Strategic Review Completed to Refocus Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value~ Updated Clinical Data on AMT-060 in Hemophilia B at Upcoming ASH Annual...
uniQure Announces Financial Results For Third Quarter 2016 and Provides Update on Company Progress
22 nov. 2016 07h00 HE
|
uniQure N.V.
~ Strategic Review Completed to Refocus Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value ~ Updated Clinical Data on AMT-060 in Hemophilia B at Upcoming ASH Annual...
uniQure Completes Strategic Review to Refocus its Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value
15 nov. 2016 07h05 HE
|
uniQure N.V.
~ Company Structure Simplified; Manufacturing to be Consolidated into Lexington, MA ~ Preparation Underway for Late-Stage Development in Hemophilia B ~ Cost Savings Expected to Extend Cash Resources...
uniQure Announces Upcoming Presentation of Data at Annual American Society of Hematology Meeting
03 nov. 2016 09h10 HE
|
uniQure N.V.
– Poster presentation on Saturday, December 3, 2016 – – Investor breakfast event on Monday, December 5 at 7:00 am PST/10:00 am EST – LEXINGTON, Mass. and AMSTERDAM, the Netherlands,...